0000950170-23-071490.txt : 20231219 0000950170-23-071490.hdr.sgml : 20231219 20231219161515 ACCESSION NUMBER: 0000950170-23-071490 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231215 FILED AS OF DATE: 20231219 DATE AS OF CHANGE: 20231219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sanchez Ramiro CENTRAL INDEX KEY: 0001830326 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39311 FILM NUMBER: 231497469 MAIL ADDRESS: STREET 1: C/O CEREVELL THERAPEUTICS HOLDINGS INC. STREET 2: 131 DARTMOUTH STREET SUITE 502 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001805387 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 844-304-2048 MAIL ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 FORMER COMPANY: FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II DATE OF NAME CHANGE: 20200303 4 1 ownership.xml 4 X0508 4 2023-12-15 0001805387 Cerevel Therapeutics Holdings, Inc. CERE 0001830326 Sanchez Ramiro C/O CEREVEL THERAPEUTICS HOLDINGS, INC. 222 JACOBS STREET, SUITE 200 CAMBRIDGE MA 02141 false true false false Chief Medical Officer false Common Stock 2023-12-15 4 M false 7500 9.88 A 7500 D Common Stock 2023-12-15 4 S false 7500 41.3857 D 0 D Stock Option (Right to Buy) 9.88 2023-12-15 4 M false 7500 0.00 D 2030-10-28 Common Stock 7500 123390 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.385 to $41.39. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 50% of the shares subject to this option vested and became exercisable on October 28, 2022, with the remainder vesting in two (2) equal annual installments thereafter. /s/ Mark Bodenrader, as Attorney-in-Fact 2023-12-19